Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 18/20 | 0.55 |
| ▸ | ADRA1D | P25100 | 16/20 | 0.55 |
| ▸ | ADRA1B | P35368 | 16/20 | 0.55 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7216965 | 0.77 | ADRA1A (0.57) | ADRA1AADRA1DADRA1BHRH1 | |
| SCHEMBL7084868 | 0.77 | ADRA1A (0.57) | ADRA1AADRA1DADRA1BHRH1 | |
| SCHEMBL7080203 | 0.75 | ADRA1A (0.52) | ADRA1AADRA1DADRA1BHRH1 | |
| SCHEMBL7530623 | 0.72 | ADRA1D (0.80) | ADRA1AADRA1DADRA1B | |
| Hydrochloric Acid SCHEMBL7141672 | 0.71 | ADRA1A (0.49) | ADRA1AADRA1DADRA1BHRH1ADRA2A | |
| SCHEMBL6963522 | 0.68 | OPRM1 (0.58) | ADRA1AADRA1DADRA1BOPRD1 | |
| SCHEMBL6963525 | 0.68 | OPRM1 (0.58) | ADRA1AADRA1DADRA1BOPRD1 | |
| SCHEMBL6955080 | 0.68 | OPRD1 (0.60) | ADRA1AADRA1DADRA1BOPRD1 | |
| SCHEMBL6955083 | 0.68 | OPRD1 (0.60) | ADRA1AADRA1DADRA1BOPRD1 | |
| SCHEMBL6966550 | 0.67 | ADRA1A (0.51) | ADRA1AADRA1DADRA1BHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620815-B1 | Selective antagonists for human alpha 1A receptors; benign prostatic hyperplasia, impotency, cardiac arrhythmia treatment; anticholesterol agents; intraocular pressure reduction | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-16 | — | — | US | disclosed |
| US-6159990-A | Oxazolidinones as α1A receptor antagonists | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |